🇺🇸 nadroparine calcium in United States

18 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 18

Most-reported reactions

1. Renal Impairment — 3 reports (16.67%)
2. Thrombosis — 3 reports (16.67%)
3. Anaemia — 2 reports (11.11%)
4. Heparin-Induced Thrombocytopenia — 2 reports (11.11%)
5. Off Label Use — 2 reports (11.11%)
6. Septic Shock — 2 reports (11.11%)
7. Acute Respiratory Failure — 1 report (5.56%)
8. Alanine Aminotransferase Increased — 1 report (5.56%)
9. Aspartate Aminotransferase Increased — 1 report (5.56%)
10. Aspiration — 1 report (5.56%)

Source database →

Frequently asked questions

Is nadroparine calcium approved in United States?

nadroparine calcium does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for nadroparine calcium in United States?

University Hospital, Geneva is the originator. The local marketing authorisation holder may differ — check the official source linked above.